已收盤 11-20 16:00:00 美东时间
-0.375
-11.23%
In a report released yesterday, Yigal Nochomovitz from Citi maintained a Buy ra...
11-05 19:16
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 无</p><blockquote><p><span style="color:#fa1432;"><strong>业绩指引与展望</strong></span></p></blockquote><p>• 无</p><blockquote><p><span style="color:#fa1432;"><strong>分业务和产品线业绩表现</strong></span></p></blockquote><p>• VIZZ(核心且唯一产品线):LENZ Therapeutics当前聚焦于单一处方药产品VIZZ,这是一款用于治疗老
11-03 13:02
进入年底,医药行业裁员消息密集释放。从跨国药企的全球降本计划,到 Biotech 因临床、商业化不及预期被动缩编,一起来看看本月行业裁员事件汇总。 10 月 ...
10-30 17:06
今日重点评级关注:Canaccord Genuity:维持Wave Life Sciences"买入"评级,目标价从42美元升至44美元;Canaccord Genuity:维持Pharming Group"买入"评级,目标价从38美元升至41美元
10-30 12:30
LENZ Therapeutics 的 2026 年第三季度财报电话会议涵盖了 260 万美元的产品收入、51% 的处方量增长、远程医疗的发展势头以及一项重大的成本重组。
10-29 21:53
LENZ Therapeutics (NASDAQ:LENZ) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below. This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit https://www.benzin...
10-29 21:24
LENZ Therapeutics ( ($LENZ) ) has provided an update. LENZ Therapeutics, Inc., ...
10-29 05:21
LENZ Therapeutics, Inc. (Nasdaq: LENZ or "LENZ" or the "Company"), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop for the treatment of presbyopia, today announced Eef Schimmelpennink, President a...
10-29 04:34
LENZ Therapeutics (NASDAQ:LENZ) reported quarterly losses of $(0.99) per share which missed the analyst consensus estimate of $(0.98) by 1.02 percent. This is a 67.8 percent decrease over losses of $(0.59) per share from the same period last year. The company reported quarterly sales of $3.384 milli...
10-29 04:33
LENZ Therapeutics reported a 50% increase in Q3 2026 VIZZ® sales and strong momentum into Q4, driven by broader consumer awareness and telehealth adoption. The company announced a strategic reorganization to prioritize consumer marketing, support market expansion, and reduce 2027 operating expenses by over 50%. Eef Schimmelpennink will transition as CEO on December 1, 2026, with Dan Chevallard appointed as Interim CEO. The company also reported Q...
10-28 20:30